CEEF1D8C-DC91-4862-86A0-F345C2C770C0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.629434954007884
- age_years
- 64
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.627
- MYC_TARGETS_V1+0.507
- E2F_TARGETS+0.502
- G2M_CHECKPOINT+0.496
- DNA_REPAIR+0.414
- WNT_BETA_CATENIN_SIGNALING+0.384
- UNFOLDED_PROTEIN_RESPONSE+0.372
- MITOTIC_SPINDLE+0.285
- NOTCH_SIGNALING+0.194
- OXIDATIVE_PHOSPHORYLATION+0.180
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.394
- IL6_JAK_STAT3_SIGNALING-0.365
- KRAS_SIGNALING_DN-0.340
- TNFA_SIGNALING_VIA_NFKB-0.280
- ALLOGRAFT_REJECTION-0.268
- INTERFERON_GAMMA_RESPONSE-0.253
- HYPOXIA-0.222
- SPERMATOGENESIS-0.219
- KRAS_SIGNALING_UP-0.210
- COMPLEMENT-0.202
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 94F9B9B1-A23E-4947-BD09-67CBA3052C51 | — | — | 0.945 |
| 2 | CA9E9B92-5D16-4455-ACC8-ACBFDFB754C5 | — | — | 0.930 |
| 3 | 5F991EDF-3871-4111-9A04-BF6CA02648CA | — | — | 0.923 |
| 4 | 3E5F6B52-112E-4F87-B49C-061B9DFD1E2D | — | — | 0.921 |
| 5 | E528D9EE-41C3-4D4C-B16F-ABBDD6E31B84 | — | — | 0.916 |
| 6 | 85D3FB91-4738-4B8A-B86E-115FDEF10166 | — | — | 0.913 |
| 7 | 30906368-89BC-42E0-8F7B-81B1DEDE812D | — | — | 0.909 |
| 8 | 4FD9ED95-21E7-440D-AAA9-86DDDF12B37A | — | — | 0.908 |
| 9 | SRR934879 | — | — | 0.907 |
| 10 | 208643FA-0388-44A3-8131-B41AC280107C | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.627 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.507 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.502 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.496 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.414 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.384 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.372 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.285 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.194 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.152 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.138 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.129 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.076 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.032 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.026 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.024 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.023 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.019 | Inavolisib | — uncovered |